Fintel reports that on December 23, 2024, Jefferies downgraded their outlook for Mesoblast Limited - Depositary Receipt () ...

The Mesoblast Ltd (ASX: MSB) share price is taking a dive today. Here’s why the biotech stock is under pressure after ...

Jefferies downgraded Mesoblast (MESO) to Hold from Buy with a price target of A$2.30, up from A$1.10. The firm updated the company’s for the ...

The drug and biotech sector had a turbulent year in 2024, starting strong but losing momentum in the second half. This ...

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Mesoblast ( (MESO) ) has shared an update.

Mesoblast (NASDAQ:MESO – Get Free Report) was downgraded by investment analysts at Jefferies Financial Group from a “buy” rating to a “hold” rating in a research report issued on Monday, MarketBeat ...

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced the Food and Drug Administration (FDA) approved Ryoncil (remestemcel-L) as the first mesenchymal ...

Mesoblast Ltd (MESO) stock saw a modest uptick, ending the day at $16.76 which represents a slight increase of $4.51 or 36.82% from the prior close of $12.25. The stock opened at $18.68 and touched a ...

Learn More The Mesoblast Ltd (ASX: MSB) share price is taking a nosedive today. Shares in the S&P/ASX 300 Index (ASX: XKO) clinical-stage biotechnology company closed yesterday trading for $3.05.

Mesoblast Limited (NASDAQ:MESO – Get Free Report) saw unusually large options trading on Thursday.Traders acquired 3,838 put options on the stock. This is an increase of 350% compared to the ...

If you thought crypto investors need to have strong stomachs, spare a thought for the investors who try their luck in the ...